Sartorius Stedim Biotech has secured exclusive global distribution rights for NanoSpark® immune cell activation reagents, investing up to US$3 million in Nanotein Technologies whilst establishing a joint development programme targeting enhanced T cell and NK cell manufacturing workflows for cellular therapy applications.

Danish pharmaceutical giant Novo Nordisk has appointed Maziar Mike Doustdar as chief executive officer, bringing his proven track record of doubling international sales over the past decade. The leadership transition coincides with strategic R&D consolidation as the company positions itself to address rapidly developing diabetes and obesity markets.

Logical Biological has established Logical Antigen, a specialist sister company focused on rapid customisation of high-quality antigens and biological materials. The new venture addresses critical supply chain challenges in the IVD market, offering streamlined protein purification services that reduce traditional development timelines from years to weeks through innovative extraction and engineering techniques.

Cambridge-based 4basebio has launched refreshed branding and a new website following its £40 million investment round, as the AIM-listed company positions itself for growth in synthetic DNA manufacturing for next-generation therapeutics including gene therapy, RNA therapeutics and vaccine development.

Clinical-stage radiopharmaceutical company ARTBIO has completed a substantial $132 million Series B financing round to advance its pipeline of alpha radioligand therapies, expand manufacturing capabilities, and support Phase II development of lead candidate AB001 for metastatic castration-resistant prostate cancer.